Journals / Turkish Journal of Urology / 2021 / Cilt: 47 - Sayı: 1

Guideline of guidelines: Muscle-invasive bladder cancer

Pages
S71–S78
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we aimed to review the 4 most commonly used guidelines from the European Association of Urology, the National Institute for Health and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Muscle-invasive bladder cancer accounts for 25% of bladder cancer cases and represents a spectrum of disease, which can result in significant morbidity and mortality for anyone affected.
📊
Key Findings & Data:It is based on a risk-benefit approach, which is often tailored to the individual requirements of patients and involves cystectomy, neoadjuvant and adjuvant therapies, and multimodal surveillance paradigms to achieve high survival rates.
💡
Conclusion & Impact:In this article, we aimed to review the 4 most commonly used guidelines from the European Association of Urology, the National Institute for Health and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Muscle-invasive bladder cancer accounts for 25% of bladder cancer cases and represents a spectrum of disease, which can result in significant morbidity and mortality for anyone affected. Current management has evolved through years of research and clinical practice. It is based on a risk-benefit approach, which is often tailored to the individual requirements of patients and involves cystectomy, neoadjuvant and adjuvant therapies, and multimodal surveillance paradigms to achieve high survival rates. Multiple guidelines exist to assist the clinicians in this decision-making process, but their adherence is often variable. In this article, we aimed to review the 4 most commonly used guidelines from the European Association of Urology, the National Institute for Health and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.

🔖

Cite This Article

OMORPHOS, N. P., PIEDAD, J. C. P., VASDEV, N. (2021). Guideline of guidelines: Muscle-invasive bladder cancer. Turkish Journal of Urology, Cilt: 47 - Sayı: 1, S71–S78. https://ajindex.com/articles/413250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ ASCO/ASTRO/SUO Guideline. J Urol 2017;198:552-9. [Crossref] 2. Nice. National Collaborating Centre for Cancer Bladder cancer Bladder cancer: diagnosis and management NICE Guideline 2 Bladder cancer: diagnosis and management Contents. 2015. 3. Witjes JA, Bruins M, Cathomas R, Compérat E, Cowan NC, Gakis G, et al. EAU Guidelines on Muscle-invasive and metastatic Bladder Cancer 2020 [Internet]. In: European Association of Urology Guidelines. 2020 Edition. European Association of Urology Guidelines Office; 2020 [cited 2020 May 21]. Available from: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-andmetastatic/ LK - Muscle-invasive and Metastatic Bladder Cancer Uroweb%7Chttp://uroweb.org/guideline/bladder-cancer-muscleinvasive-and-metastatic/%7C FG - 0 4. Flaig TW, Spiess PE, Chair V, Agarwal N, Bangs R, Patient Advocate M, et al. NCCN Guidelines Version 5.2020 Bladder Cancer. 2020. 5. Eble JN. World Health Organization Classification of Tumours. Pathol Genet Tumours Urin Syst Male Genit Organs 2004;10. 6. Mostofi FK. International classification of tumours. Histol Classif Urin Bl tumours 1973; 7. Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, et al. Molecular markers in bladder cancer. World J Urol 2019;37:31-40. [Crossref] 8. Wijkström H, Norming U, Lagerkvist M, Nilsson B, Näslund I, Wiklund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: A long-term follow-up of 276 consecutive patients. Br J Urol 1998;81:686-91. [Crossref] 9. Mariappan P, Zachou A, Grigor KM. Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience. Eur Urol 2010;57:843-9. [Crossref] 10. Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, et al. Blue light cystoscopy for the diagnosis of bladder cancer_ Results from the US prospective multicenter registry. Urol Oncol 2018;36:361.e1-361.e6. [Crossref] 11. Zang Z, Wu Q, Chiong E. Blue-light cystoscopy and narrowband imaging in bladder cancer management. Formos J Surg 2019;52:155. [Crossref] 12. Maruschke M, Kram W, Zimpfer A, Kundt G, Hakenberg OW. Upper Urinary Tract Tumors: Which Diagnostic Methods Are Needed? Urol Int 2017;98:304-11. [Crossref